Novo Nordisk A/S Annual Report 2024. 104 rows view the latest nvo 10k form and other securities and exchange commission (sec) filings for novo nordisk a/s (nyse:nvo) at marketbeat. In the first quarter of 2024, novo nordisk successfully completed the flow kidney outcomes trial with semaglutide 1.0 mg.

Here you can find webcasts, presentations and relevant documents from our last novo nordisk annual general meeting. In the first quarter of 2024, novo nordisk successfully completed the flow kidney outcomes trial with semaglutide 1.0 mg.